Cargando…

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

Detalles Bibliográficos
Autor principal:	Blair, Hannah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294813/ https://www.ncbi.nlm.nih.gov/pubmed/31329656 http://dx.doi.org/10.1007/s40265-018-1034-z

Ejemplares similares

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine
por: Hwang, Yu-Yan, et al.
Publicado: (2012)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
por: van Eijkelenburg, Natasha K.A., et al.
Publicado: (2018)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
por: Jost, Felix, et al.
Publicado: (2019)

Cytarabine/daunorubicin: Coronavirus disease-2019 pneumonia: case report
Publicado: (2021)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine
por: Brandt, K., et al.
Publicado: (2010)

Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976)

Correction: Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4
por: Hu, Tianzhen, et al.
Publicado: (2022)

Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007)

The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials
por: Wang, Hanyu, et al.
Publicado: (2020)

Cytarabine/daunorubicin: Infections and flare-up of ulcer and cellulitis: 2 case reports
Publicado: (2022)

Correction: Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines
por: Tiziani, Stefano, et al.
Publicado: (2009)

Thrombotic Microangiopathy with Skin Localization Secondary to Cytarabine-Daunorubicin Association: Report of a Case
por: Regragui, S., et al.
Publicado: (2012)

Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
por: Galettis, P., et al.
Publicado: (1994)

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
por: Burnett, A K, et al.
Publicado: (2017)

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia
por: Fordham, S E, et al.
Publicado: (2015)

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation
por: Sanna, Marco, et al.
Publicado: (2013)

Author Correction: Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
por: Hubeek, I, et al.
Publicado: (2005)

Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia
por: Wang, Biao, et al.
Publicado: (2020)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model
por: Xu, Haiyan, et al.
Publicado: (2019)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
por: Suo, Xiaohui, et al.
Publicado: (2023)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial
por: Drevin, Guillaume, et al.
Publicado: (2022)

Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment
por: Al-Aamri, Hussain Mubarak, et al.
Publicado: (2021)

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
por: Heuser, Michael, et al.
Publicado: (2021)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018)

Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia
por: Al-Aamri, Hussain Mubarak, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_10tuvg7t9lk5b0n8e51vt69qcl